Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2017

01-04-2017 | Original Article

Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis

Authors: Mei Feng, Jing Zhu, Liqun Liang, Ni Zeng, Yanqiu Wu, Chun Wan, Yongchun Shen, Fuqiang Wen

Published in: International Journal of Clinical Oncology | Issue 2/2017

Login to get access

Abstract

Background

Pleural effusion is one of the most common complications of lung adenocarcinoma and is diagnostically challenging. This study aimed to investigate the diagnostic performance of carcinoembryonic antigen (CEA), cytokeratin fragment (CYFRA) 21-1, and cancer antigen (CA) 19-9 for lung adenocarcinoma-associated malignant pleural effusion (MPE) through a validation study and meta-analysis.

Methods

Pleural effusion samples were collected from 81 lung adenocarcinoma-associated MPEs and 96 benign pleural effusions. CEA, CYFRA 21-1, and CA19-9 were measured by electrochemiluminescence immunoassay. The capacity of tumor markers was assessed with receiver operating characteristic curve analyses and the area under the curve (AUC) was calculated. Standard methods for meta-analysis of diagnostic studies were used to summarize the diagnostic performance of CEA, CYFRA 21-1, and CA19-9 for lung adenocarcinoma-associated MPE.

Results

The pleural levels of CEA, CYFRA 21-1, and CA19-9 were significantly increased in lung adenocarcinoma-associated MPE compared to benign pleural effusion. The cut-off points for CEA, CYFRA 21-1, and CA19-9 were optimally set at 4.55 ng/ml, 43.10 μg/ml, and 12.89 U/ml, and corresponding AUCs were 0.93, 0.85, and 0.81, respectively. The combination of CEA, CYFRA 21-1, and CA19-9 increased the sensitivity to 95.06%, with an AUC of 0.95. Eight studies were included in this meta-analysis. CEA showed the best diagnostic performance with pooled sensitivity, specificity, positive/negative likelihood ratio, and diagnostic odds ratio of 0.75, 0.96, 16.01, 0.23, and 81.49, respectively. The AUC was 0.93.

Conclusions

CEA, CYFRA 21-1, and CA19-9 play a role in the diagnosis of lung adenocarcinoma-associated MPE. The combination of these tumor markers increases the diagnostic accuracy.
Literature
2.
3.
go back to reference Zugazagoitia J, Enguita AB, Nuñez JA et al (2014) The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis 6:S526–S536PubMedPubMedCentral Zugazagoitia J, Enguita AB, Nuñez JA et al (2014) The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis 6:S526–S536PubMedPubMedCentral
4.
go back to reference Tang Y, He Z, Zhu Q et al (2014) The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis 6:S589–S596PubMedPubMedCentral Tang Y, He Z, Zhu Q et al (2014) The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis 6:S589–S596PubMedPubMedCentral
5.
go back to reference Kasapoglu US, Arınç S, Gungor S et al (2015) Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin Respir J. doi:10.1111/crj.12292 PubMed Kasapoglu US, Arınç S, Gungor S et al (2015) Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin Respir J. doi:10.​1111/​crj.​12292 PubMed
6.
go back to reference Wu SG, Yu CJ, Tsai MF et al (2013) Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J 41:1409–1418CrossRefPubMed Wu SG, Yu CJ, Tsai MF et al (2013) Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J 41:1409–1418CrossRefPubMed
7.
go back to reference Marel M, Stastny B, Melínová L et al (1995) Diagnosis of pleural effusions. Experience with clinical studies, 1986–1990. Chest 107:1598–1603CrossRefPubMed Marel M, Stastny B, Melínová L et al (1995) Diagnosis of pleural effusions. Experience with clinical studies, 1986–1990. Chest 107:1598–1603CrossRefPubMed
8.
go back to reference Porcel JM, Palma R, Bielsa S et al (2015) TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology 20:831–833CrossRefPubMed Porcel JM, Palma R, Bielsa S et al (2015) TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology 20:831–833CrossRefPubMed
9.
go back to reference Lombardi G, Zustovich F, Nicoletto MO et al (2010) Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 33:420–423CrossRefPubMed Lombardi G, Zustovich F, Nicoletto MO et al (2010) Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 33:420–423CrossRefPubMed
10.
go back to reference Shi HZ, Liang QL, Jiang J et al (2008) Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 13:518–527CrossRefPubMed Shi HZ, Liang QL, Jiang J et al (2008) Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 13:518–527CrossRefPubMed
11.
go back to reference Nguyen AH, Miller EJ, Wichman CS et al (2015) Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res 166:432–439CrossRefPubMedPubMedCentral Nguyen AH, Miller EJ, Wichman CS et al (2015) Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res 166:432–439CrossRefPubMedPubMedCentral
12.
go back to reference Pang C, Wu Y, Wan C et al (2016) Accuracy of the bronchoalveolar lavage enzyme-linked immunospot assay for the diagnosis of pulmonary tuberculosis: a meta-analysis. Medicine (Baltimore) 95:e3183CrossRef Pang C, Wu Y, Wan C et al (2016) Accuracy of the bronchoalveolar lavage enzyme-linked immunospot assay for the diagnosis of pulmonary tuberculosis: a meta-analysis. Medicine (Baltimore) 95:e3183CrossRef
13.
go back to reference Whiting PF, Weswood ME, Rutjes AW et al (2006) Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 6:9CrossRefPubMedPubMedCentral Whiting PF, Weswood ME, Rutjes AW et al (2006) Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 6:9CrossRefPubMedPubMedCentral
14.
go back to reference Huang WW, Tsao SM, Lai CL et al (2010) Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology 42:224–228CrossRefPubMed Huang WW, Tsao SM, Lai CL et al (2010) Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology 42:224–228CrossRefPubMed
15.
go back to reference Han HS, Yun J, Lim SN et al (2013) Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer 133:645–652CrossRefPubMed Han HS, Yun J, Lim SN et al (2013) Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer 133:645–652CrossRefPubMed
16.
go back to reference Hsieh TC, Huang WW, Lai CL et al (2013) Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions. Cancer Cytopathol 121:483–488CrossRefPubMed Hsieh TC, Huang WW, Lai CL et al (2013) Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions. Cancer Cytopathol 121:483–488CrossRefPubMed
17.
go back to reference Lv M, Mou Y, Wang P et al (2013) Diagnostic and predictive role of cell-free midkine in malignant pleural effusions. J Cancer Res Clin Oncol 139:543–549CrossRefPubMed Lv M, Mou Y, Wang P et al (2013) Diagnostic and predictive role of cell-free midkine in malignant pleural effusions. J Cancer Res Clin Oncol 139:543–549CrossRefPubMed
18.
go back to reference Wang Y, Chen Z, Chen J et al (2013) The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer. Clin Chim Acta 421:230–235CrossRefPubMed Wang Y, Chen Z, Chen J et al (2013) The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer. Clin Chim Acta 421:230–235CrossRefPubMed
19.
go back to reference Shin YM, Yun J, Lee OJ et al (2014) Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer Res Treat 46:178–185CrossRefPubMedPubMedCentral Shin YM, Yun J, Lee OJ et al (2014) Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer Res Treat 46:178–185CrossRefPubMedPubMedCentral
20.
go back to reference Son SM, Han HS, An JY et al (2015) Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Pathology 47:123–129CrossRefPubMed Son SM, Han HS, An JY et al (2015) Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Pathology 47:123–129CrossRefPubMed
21.
go back to reference Botana-Rial M, De Chiara L, Valverde D et al (2012) Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma. Cancer Biol Ther 13:1436–1442CrossRefPubMedPubMedCentral Botana-Rial M, De Chiara L, Valverde D et al (2012) Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma. Cancer Biol Ther 13:1436–1442CrossRefPubMedPubMedCentral
22.
go back to reference Wu GP, Zhang SS, Fang CQ et al (2008) Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions. Cytopathology 19:212–217CrossRefPubMed Wu GP, Zhang SS, Fang CQ et al (2008) Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions. Cytopathology 19:212–217CrossRefPubMed
23.
go back to reference Wang XF, Wu YH, Wang MS et al (2014) CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev 15:363–368CrossRefPubMed Wang XF, Wu YH, Wang MS et al (2014) CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev 15:363–368CrossRefPubMed
24.
go back to reference Wang YX, Hu D, Yan X (2013) Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci 17:2383–2389PubMed Wang YX, Hu D, Yan X (2013) Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci 17:2383–2389PubMed
25.
go back to reference Ono A, Takahashi T, Mori K (2013) Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer 13:354CrossRefPubMedPubMedCentral Ono A, Takahashi T, Mori K (2013) Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer 13:354CrossRefPubMedPubMedCentral
26.
go back to reference Huang Z, Liu F (2014) Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol 35:7459–7465CrossRefPubMed Huang Z, Liu F (2014) Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol 35:7459–7465CrossRefPubMed
27.
go back to reference Antonangelo L, Sales RK, Corá AP et al (2015) Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results. Curr Oncol 22:e336–e341CrossRefPubMedPubMedCentral Antonangelo L, Sales RK, Corá AP et al (2015) Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results. Curr Oncol 22:e336–e341CrossRefPubMedPubMedCentral
Metadata
Title
Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
Authors
Mei Feng
Jing Zhu
Liqun Liang
Ni Zeng
Yanqiu Wu
Chun Wan
Yongchun Shen
Fuqiang Wen
Publication date
01-04-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1073-y

Other articles of this Issue 2/2017

International Journal of Clinical Oncology 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine